8-KCorporate ChangesExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Bylaw Amendment (Feb 22, 2022)

Filed February 22, 2022For Securities:ABT

Summary

Abbott Laboratories (ABT) has filed an 8-K report primarily detailing an amendment to its bylaws concerning the size of its Board of Directors. Effective April 29, 2022, the Board of Directors will be reduced from thirteen to twelve members. This change, approved by the Board of Directors on February 18, 2022, revises Article III, Section 2 of Abbott's bylaws. While this is a procedural change related to corporate governance, investors should note that such adjustments in board size can sometimes precede or accompany other strategic shifts, though no specific strategic implications are mentioned in this filing. The filing also includes updated bylaws and cover page interactive data. The report was signed by Robert E. Funck, Jr., Executive Vice President, Finance and Chief Financial Officer.

Key Highlights

  • 1Abbott Laboratories' Board of Directors size is set to decrease from thirteen to twelve members.
  • 2The amendment to the bylaws is effective April 29, 2022.
  • 3The change was approved by the Board of Directors on February 18, 2022.
  • 4This amendment affects Article III, Section 2 of Abbott's bylaws.
  • 5The filing is classified under Item 5.03 (Amendments to Articles of Incorporation or Bylaws) and Item 9.01 (Financial Statements and Exhibits).
  • 6The report was signed by the CFO, Robert E. Funck, Jr.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report an amendment to Abbott Laboratories' bylaws that reduces the size of its Board of Directors from thirteen to twelve members, effective April 29, 2022.

The filing does not provide a specific reason for the reduction in board size. It only states that the Board of Directors approved the amendment to the bylaws on February 18, 2022.

This filing solely addresses a governance matter – the size of the Board of Directors. It does not provide any information or indication of underlying strategic shifts or operational changes within the company. Investors should look to other communications from the company for strategic updates.

The filing was signed by Robert E. Funck, Jr., who holds the positions of Executive Vice President, Finance and Chief Financial Officer of Abbott Laboratories.